- Home
- CIEN vs CORT Comparison
CIEN vs CORT Comparison
Compare CIEN & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIEN | CORT |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4B | 8.6B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | CIEN | CORT |
|---|---|---|
| Price | $258.50 | $37.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 6 |
| Target Price | ★ $219.29 | $111.00 |
| AVG Volume (30 Days) | ★ 2.9M | 2.7M |
| Earning Date | 12-11-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | N/A |
| EPS | 0.85 | ★ 0.87 |
| Revenue | ★ $4,769,507,000.00 | $741,172,000.00 |
| Revenue This Year | $27.20 | $23.96 |
| Revenue Next Year | $15.92 | $43.40 |
| P/E Ratio | $299.05 | ★ $40.96 |
| Revenue Growth | ★ 18.79 | 17.92 |
| 52 Week Low | $49.21 | $32.99 |
| 52 Week High | $254.82 | $117.33 |
Technical Indicators
Market Signals| Indicator | CIEN | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 66.43 | 20.03 |
| Support Level | $221.12 | $34.28 |
| Resistance Level | $242.51 | $85.34 |
| Average True Range (ATR) | 12.27 | 3.71 |
| MACD | 1.28 | -5.58 |
| Stochastic Oscillator | 99.72 | 7.98 |
Price Performance
Historical ComparisonAbout CIEN Ciena Corporation
Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.